warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Brief Description  
This randomized phase III trial is studying giving octreotide together with interferon alfa-2b to see how well it works compared with giving octreotide together with bevacizumab in treating patients with metastatic or locally advanced, high-risk neuroendocrine tumor. This project is being conducted at the following locations: Carolinas Medical Center/Blumenthal Cancer Center, Carolinas Hematology-Oncology Associates, and Mecklenburg Medical Group.
Who may be Eligible  

Patients, ages 18 and over, may be eligible if they meet the following criteria:
  • Diagnosis of unresectable metastatic or locally advanced, low- or intermediate-grade neuroendocrine carcinoma, including the following subtypes
    • Carcinoid tumor, low-grade or well differentiated neuroendocrine carcinoma
    • Atypical carcinoid tumor, intermediate-grade or moderately differentiated neuroendocrine carcinoma
  • High-risk disease as defined by at least one of the following:
    • Progressive disease
    • Refractory carcinoid syndrome while receiving octreotide acetate (i.e., defined by > 2 flushing episodes/day or > 4 bowel movements/day)
    • Atypical histology and more than 6 lesions
    • Metastatic colorectal carcinoid tumor
      • Patients with metastatic cecal or appendiceal carcinoid tumor are not eligible unless they fit other mentioned high-risk features
    • Metastatic gastric carcinoid tumor
  • Measurable disease
  • Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible
  • No osseous metastasis as only site of disease
  • No medullary thyroid carcinoma or islet cell carcinoma
  • No history of primary brain tumor or metastatic cancer to the brain
Speciality/Disorder  
Gastrointestinal Cancer
IRB Number  
05-08-12B
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Email:  Delois.DeShazo@carolinashealthcare.org
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203
Close